GlassScriptPhysician profile
Ousama Alkhatib
NPI 1093283905
$5,507.81
in general payments reported to CMS, 2019-2025
31 companies · $1,732 in 2025
The $1,732 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $217 · 2023: $1,414 · 2024: $2,146 · 2025: $1,732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,290.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,689.73 | 2022-2025 | Rinvoq, Skyrizi, Mavyret |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $476.98 | 2023-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $334.15 | 2023-2025 | Stelara, Simponi Aria, Simponi |
| Genzyme Corporation | $292.89 | 2023-2025 | |
| Ardelyx, INC. | $279.03 | 2022-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $268.69 | 2022-2025 | Entyvio, Eohilia |
| Madrigal Pharmaceuticals | $155.72 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $138.58 | 2022-2024 | Sucraid, Sucraid |
| Aimmune Therapeutics, INC. | $94.43 | 2024-2025 | Vowst |
| Phathom Pharmaceuticals, INC. | $76.21 | 2023-2025 | Voquezna |
| Celltrion USA INC. | $68.99 | 2025 | Vegzelma |
| Pfizer INC. | $59.28 | 2023-2024 | |
| Fresenius Kabi USA, LLC | $55.66 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.49 | 2024 | Cyltezo |
| Braintree Laboratories, INC. | $51.21 | 2024-2025 | Suflave, Sutab |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $50.58 | 2024 | Cologuard Collection Kit |
| Intercept Pharmaceuticals, INC. | $38.41 | 2023-2025 | Ocaliva |
| Evoke Pharma, INC. | $33.69 | 2022-2023 | Gimoti |
| Regeneron Healthcare Solutions, INC. | $33.05 | 2025 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $32.70 | 2025 | Iqirvo |
| Daiichi Sankyo INC. | $29.36 | 2022 | |
| Biocon Biologics INC | $26.23 | 2025 | Hulio |
| Sandoz INC. | $25.87 | 2023 | Hyrimoz |
| Vivus LLC | $21.54 | 2024 | Qsymia |
| Celgene Corporation | $20.86 | 2024 | Zeposia |
| Albireo Pharma, INC. | $19.29 | 2024 | Iqirvo |
| Novo Nordisk INC | $18.75 | 2023 | |
| Ferring Pharmaceuticals INC. | $17.24 | 2024 | Rebyota |
| Nestle Healthcare Nutrition INC. | $17.08 | 2023 | |
| Lilly USA, LLC | $15.04 | 2025 | Omvoh |
| Redhill Biopharma INC. | $14.08 | 2023 | Talicia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ousama Alkhatib listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.